Scientific Symposium

Advances in Lipid and LNP Development and Manufacturing

June 5, 2024​​ | Cambridge, United Kingdom


Overview

Lipids are among the most clinically important excipients for drug delivery systems and are especially relevant for RNA-based therapies and mRNA vaccines. In this symposium, you will gain valuable insights into the use of lipids in drug delivery and the steps that lead to success. Our team will outline the role of our novel multivariate models to speed up timelines and increase successful scale up and transfer to the clinic. We will also highlight current advances in leveraging novel lipids, such as randomized PEGs (rPEGs), ionizable lipids in lipid nanoparticle (LNP)-based delivery systems and encapsulation technologies. As part of the symposium you will have the opportunity to network over lunch.

With decades of experience and expertise in every step of the manufacturing process, including route scouting, process development and optimization, purification, isolation, characterization, scale up and commercialization, Evonik is your partner to help your drug delivery project succeed.


Key learnings for participants

  • Discover the essential capabilities required to support lipid development and manufacturing
  • Learn about innovative techniques for liposome processing that can help you improve the efficiency and effectiveness of your drug delivery systems
  • Explore the latest advancements in LNP formulation, including the use of randomized PEGs (rPEGs) and ionizable lipids, and how they can enhance the efficacy and safety of your drug delivery systems 



Note: Please fill in your details and click 'Submit' to register for the workshop. Once we have received your registration, we will send you a status notification as soon as possible. Due to the high demand for our workshops, we sometimes need to reject registrations or put you on a waiting list. Workshop materials will be available for download at the end of the workshop. Any photographs taken during the event are the property of Evonik and may be used for promotional purposes.


Details
Participation fee: Free of charge 
Workshop language: English



Agenda
The workshop will start at 09:30 on Wednesday, June 5, 2024, and finish at 14:30 on the same day. To see the detailed workshop program please click here.



Venue
The workshop will take place at:
Babraham Research Campus
Babraham Hall, Babraham
Cambridge CB22 3AT
United Kingdom

Fill out the form to register for the workshop:

Agenda

09:30-10:00 | Registration and Coffee/Tea​

10:00-10:15 | Introduction to Evonik Health Care
Dominic Walsh
Regional Business Manager UK
Evonik Health Care

10:15-11:00 | Leading the way in lipid production
Dr. Ulrich Klockner
Head of Process Development
Evonik Health Care

11:00-11:45 | New families of ionizable lipids for effective delivery of RNA therapeutics​
Diego De Miguel Samaniego
Formulation Manager
CerTest Pharma

11:45-13:00 | Networking Lunch

13:00-13:30 | From PEG to rPEGs: A unique building block in next generation lipid nanoparticles
Dr. Sophie Hammer
Senior Manager Strategic & Technical Marketing
Evonik Health Care

13:30-14:00 | 3D printed microfluidic arrays for the development of liposomes
Prof. Dennis Douroumis
Professor in Pharmaceutical Technology and Process Engineering
Greenwich University

14:00-14:15 | Overview of Evonik's  parenteral CDMO services
George Smith
Senior Business Manger Parenteral Services
Evonik Health Care

14:15-14:30 | Wrap up and Goodbye






Disclaimer

Notice for business transactions
We assume that you are not currently or foreseeably involved in a business decision in favour of or in direct connection with the Evonik Group or, if this is the case, the decision will not be influenced by this invitation. Therefore, we do not see any concerns on our part regarding your participation. However, we would like to ask you to ensure that you are allowed to accept the invitation in accordance with the regulations that apply to you.

Note for public officials
We assume that you are not or have not been involved in any official act in favour of or in connection with the Evonik Group, either now or in the foreseeable future or in the past and therefore your participation in the event is not subject to any concerns. In addition, we ask you to ensure that your superior approves your participation or you may also accept the invitation in accordance with the rules applicable to you. By registering or participating, you confirm to us that the acceptance of this invitation is permitted according to your internal rules and that you have obtained all necessary approvals. If this is not the case, we ask you for a corresponding note.

Tax notices
Any tax liability resulting from this event will be borne by Evonik Industries AG through a flat-rate tax levy pursuant to Section 37b of the German Income Tax Act (EStG). If you are not taxable in Germany, please clarify whether you must report the invitation to your employer for taxation or whether taxation must be made via your income tax return.




QUESTIONS? 

George Smith
Senior Business Manager Parenteral Drug Delivery EMEA
+44 (0) 7496 257839

Cléa Michel

Cléa Michel is product manager for Cell Culture Ingredients at Evonik Health Care. She provides biopharma companies and media manufacturers with the finest specialty ingredients to increase cell culture performance. Cléa has a background in biochemistry and biotechnology engineering and holds a master’s degree from the National Institute of Applied Sciences in Lyon, France. She has held various positions in marketing, project management and business development and is passionate about innovative solutions that enable the successful development of life-saving biopharmaceuticals.
Dr. Stephan Brinkmann

Stephan Brinkmann works as project manager and head of Evonik's Biopharma Applications group at Evonik R&D for the Health Care business line. He is responsible for biopharma innovation projects as well as application tests of Evonik's cell culture ingredients (i.e., cQrex® peptides). Stephan studied molecular biotechnology at Bielefeld University in Germany, where he specialized in biopharma upstream and downstream process development. Before joining Evonik, Stephan worked in Switzerland on industrial mammalian cell line development for the production of therapeutic biologics. Stephan obtained his Ph.D. in a public private partnership with Sanofi and later Evotec at Fraunhofer IME in Giessen with a focus on the discovery of natural products, especially peptides.